Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

Radiogenomics, focusing on the relationship between genomics and imaging phenotypes,
has been widely applied to address tumour heterogeneity and predict immune …

Diagnostics require precision and predictive ability to be clinically useful. Integration of multi-
omic with clinical data is crucial to our understanding of disease pathogenesis and …

Early detection, accurate monitoring, and therapeutics are major problems in non‐small‐cell
lung cancer (NSCLC) patients. We identified genomic copy number variation of a unique …

Aims Oncotype DX recurrence score (RS) is a clinically validated assay, which predicts the
likelihood of disease recurrence in oestrogen receptor‐positive/HER2‐negative …

Simple Summary Molecular diagnostic tests can facilitate molecular classification of breast
cancer and its clinical management, including prediction, prognosis, and selection of …

Simple Summary The preoperative definition of the Oncotype DX recurrence score would be
critical to identify breast cancer patients who could benefit from chemotherapy before …

Ductal carcinoma in situ (DCIS) represents 20% of all breast cancers. The treatment
paradigm for the majority of patients with DCIS consists of breast-conserving surgery (BCS) …

Background Background parenchymal enhancement (BPE) at dynamic contrast-enhanced
(DCE) MRI of cancer-free breasts increases the risk of developing breast cancer; …

Background Tumoral hypoxia is associated with aggressiveness in many cancers including
breast cancer. However, measuring hypoxia is complicated. Carbonic anhydrase IX (CAIX) …